UNSPSC 51362006: Flurazepam hydrochloride

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 756RDM536M, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but more generally known as flurazepam dihydrochloride, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02238MIG.

UNSPSC 51362006 Flurazepam hydrochloride is a Commodity code for a specific pharmaceutical product, but the recent state and local procurement activity tagged under this code does not align with its nominal scope. Seminole County, Florida's IFB60459723LAS solicitation, posted on June 30, 2026, seeks procurement of naloxone and safe drug deactivation systems for community health initiatives — neither of which are flurazepam hydrochloride. The mismatch suggests either a data-entry error in the tagging or a significant divergence between the code's intended use and how it is being applied in the field. State and local procurement offices use UNSPSC codes inconsistently, and pharmaceutical codes in particular show classification variance across jurisdictions. Without additional recent opportunities properly tagged to this code, the actual pattern of state and local demand for flurazepam hydrochloride cannot be determined.

The single recent opportunity on record involves Seminole County, Florida, procuring naloxone and drug deactivation systems through competitive bidding with a response deadline of July 26, 2023, and quarterly deliveries required to the Seminole County Community Health Building in Sanford, Florida. The contract term includes an initial two-year period with a one-year renewal option. Bidders must provide unit costs, comply with E-Verify requirements, and maintain specified insurance coverage including workers' compensation and commercial general liability. The source provides no additional state or local opportunities properly aligned with flurazepam hydrochloride procurement, indicating this code sees little recent relevant activity in state and local markets.